Psoriasis

Disease State Hub

FDA Alerts

FDA ALERT

FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions

11/08/2015

Anthony Calabro, MA

The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.

11/08/2015

Research Summaries

FDA ALERT

FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions

11/30/2023

Anthony Calabro, MA

The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.

11/30/2023

research summary

research summary

Drug Survival, Effectiveness of IL-23 Inhibitors for Psoriasis, PsA

10/26/2023

Leigh Precopio

Despite being approved for use, consensus among the real-world data on the use of IL-23 inhibitors in psoriatic disease has been lacking; therefore, researchers recently examined the drug survival and...

10/26/2023

Research summary

Can a Novel Tool Predict the Risk of Developing Psoriatic Arthritis Among Those With Psoriasis?

10/13/2023

Anthony Calabro, MA

Researchers aimed to develop a risk prediction model for psoriatic arthritis progression in patients with psoriasis.

10/13/2023

Research Summary

Secukinumab, Adalimumab Show Similar Efficacy for Enthesitis Resolution in Patients With Psoriatic Arthritis at 52 Weeks

08/10/2023

Anthony Calabro, MA

In a post hoc analysis of the EXCEED study, researchers found that secukinumab and adalimumab—two biologic disease-modifying antirheumatic medications—showed similar efficacy in the resolution of enthesitis...

08/10/2023

research summary

Ultrasound Is Effective as Subclinical PsA Screening Tool

03/21/2023

The authors of a recent study aimed to determine if the use of routine ultrasound could be an effective tool for screening patients with psoriasis for subclinical psoriatic arthritis.

03/21/2023

April 2024

Current Issue

April 2024

Volume 64

Issue 4